Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.

Cancer Res Commun · 2023 · PMC10414130 · PMID 37575280

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

did not reach statistical significanceP < 0.1so close (0.05 < p ≤ 0.1)

Cytotoxic cells, PD-1, CD45, CD8 T cells, Lymphoid, CTLA4, IFN gamma signature scores were also higher in responders compared with non-responders, but this comparison did not reach statistical significance ( P < 0.1; Supplementary Fig.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.